To explore the therapeutic effect of GLS1 inhibitor CB-839 on liver cancer cells, we treated the panel of 11 liver cancer cell lines with increasing concentrations of CB-839 in long-term colony formation assays and short-term CellTiter-Blue cell viability assays. This evidence concerns the gene GLS and liver cancer.